Some pulsed laser energy transmitting catheters currently used for ablating and clearing blockages in human arteries may use a single large diameter fiber optic which tends to be stiff for some such indications. For improved catheter flexibility, multiple smaller diameter fiber optics may be used which are arranged in various shaped bundles. In some cases, excimer laser ablation efficiency of atheroma may be inversely proportional to the relative amount of inactive surface area or dead space at the ablation catheter tip contacting the target surface being ablated. Multiple fiber optic based catheters may have a significant amount of dead space, which may be due to the cladding, buffer, fiber packing factor, glue and the sidewall of the catheter outside tubing along with a guidewire lumen tubing or the like.
A doctoral thesis by Hamburger showed ablation histology for multiple fiber optic bundle ablation catheters versus a single fiber optic and indicated that the dead space leads to more tissue damage and less efficient ablation than a window tip with a homogonous energy distribution ablating surface, “New Aspects of Excimer Laser Coronary Angioplasty Physical Aspects and Clinical Results, printed by Optima Grafische Communicatie ISBN 90-73235-27-8, Rotterdam, Jaap N. Hamburger, 1999. Hamburger's conclusions stated that: “Optimization of excimer laser coronary angioplasty can be achieved by elimination of ultraviolet-absorbing media, reduction of catheter advancement speeds and by reduction of the non-light emitting area at the tip of a laser catheter.” What are needed are catheter device configurations and methods for use thereof which allow for increased optical beam expansion of the optical beam which exits the distal portion of the catheter and which reduce dead space due to catheter elements which encompass an optical window at a distal portion of a laser catheter.
Some embodiments of a laser ablation catheter to ablate blockages in body lumens using high energy and high power laser pulses include a liquid filled waveguide. The liquid filled waveguide may include an elongate catheter body tube having an inner surface with a first index of refraction and a biocompatible ultraviolet transparent optical fluid disposed within and completely filling a core liquid volume of the elongate catheter body tube which is at least partially bounded by the inner surface, with the optical fluid having a second index of refraction which is greater than the first index of refraction. The laser ablation catheter may also include an ultraviolet grade elongated distal optical window disposed in liquid sealed relation to a surface of the elongate catheter body tube at a distal end of the elongate catheter body tube. The distal optical window may further have an insert segment which is disposed within a distal section of the elongate catheter body tube and which includes a core and cladding configured to act as a waveguide. The distal optical window may also have an expanded segment which is disposed distally of the insert segment, which does not have a core and cladding configured to act as a waveguide, which has an outer diameter which is greater than an outer diameter of the insert segment, which has an output surface that has an area which is equal to or greater than an area of a transverse section of the elongate catheter body tube proximally adjacent the distal optical window and which has an axial length sufficient to allow optical energy expansion within the expanded segment such that a optical energy emitted from the output surface produces a hole in target tissue having a diameter equal to or greater than an outer diameter of the elongate catheter body tube proximally adjacent the distal optical window.
Some embodiments of a laser ablation catheter to ablate blockages in body lumens using high energy laser pulses with a pulse duration of less than 100 nanoseconds may include a liquid filled waveguide including an elongate catheter body tube having an inner surface with a first index of refraction and a biocompatible ultraviolet transparent optical fluid disposed within and completely filling an inner lumen of the elongate catheter body tube, with the optical fluid having a second index of refraction which is greater than the first index of refraction. Such laser ablation catheters may also include an ultraviolet grade elongated distal optical window disposed in liquid sealed relation to a surface of the elongate catheter body tube at a distal end of the elongate catheter body tube. The distal optical window may further have an insert segment which is disposed within a distal section of the elongate catheter body tube and which comprises an ultraviolet grade material. A layer of material may be disposed about an outer surface of the insert segment which includes an index of refraction lower than an index of refraction of the material of the insert segment or a reflective material. In addition, the distal optical window may further include an expanded segment which is disposed distally of the insert segment, which is not configured to act as a waveguide, which has an outer diameter which is greater than an outer diameter of the insert segment, which has an output surface that has an area which is equal to or greater than an area of a transverse section of the elongate catheter body tube proximally adjacent the distal optical window and which has an axial length sufficient to allow optical energy expansion within the expanded segment such that optical energy emitted from the output surface ablates a hole in target tissue having a diameter equal to or greater than an outer diameter of the elongate catheter body tube proximally adjacent the distal optical window.
Some embodiments of a laser ablation catheter to ablate blockages in body lumens may include a liquid filled waveguide including an elongate catheter body tube having an inner layer with a first index of refraction and a biocompatible ultraviolet transparent optical fluid disposed within and completely filling a core liquid volume of the elongate catheter body tube, with the optical fluid having a second index of refraction which is greater than the first index of refraction. The laser ablation catheter may also include a distal optical window disposed in liquid sealed relation to the elongate catheter body tube at a distal end of the elongate catheter body tube. The distal optical window may further have an insert segment which is disposed within a distal section of the catheter body tube and which includes a core and cladding configured to act as a waveguide. An expanded segment may be disposed distally of the insert segment which is not configured to act as a waveguide, which has an outer diameter which is greater than an outer diameter of the insert segment, which has an output surface that has an area which is equal to or greater than an area of a transverse section of the elongate catheter body tube proximally adjacent the distal optical window and which has an axial length sufficient to allow optical energy expansion within the expanded segment such that optical energy emitted from the output surface produces a hole in target tissue having a diameter equal to or greater than an outer diameter of the elongate catheter body tube proximally adjacent the distal optical window.
Certain embodiments are described further in the following description, examples, claims and drawings. These features of embodiments will become more apparent from the following detailed description when taken in conjunction with the accompanying exemplary drawings.
The drawings illustrate embodiments of the technology and are not limiting. For clarity and ease of illustration, the drawings may not be made to scale and, in some instances, various aspects may be shown exaggerated or enlarged to facilitate an understanding of particular embodiments.
Laser ablation catheters and laser delivery systems in general have a wide range of applications in the medical field. Such systems may be used to deliver laser energy to desired sites of a patient's anatomy, and may be particularly suitable for delivering laser energy to locations inside a patient's body that allow for minimally invasive treatment of a variety of indications using a variety of treatment modalities. Example of some treatment modalities include, heating tissue, stimulating tissue, drug activation within a patient's tissue and ablation of tissue or other organic or calcium materials within a patient. Some examples of clinical indications for laser treatment may include laser atherectomy and the use of a laser catheter to cross total or partial occlusions of body vessels.
One drawback of some current laser systems is the cost of the systems and devices used to deliver the laser energy, particularly those components that are designated as single use products. Liquid core laser ablation catheter embodiments may generally be considerably less expensive than a silica fiber optic based laser catheter and may also have less dead space at the ablation tip for contact cutting. Liquid filled ablation catheters may eliminate most of the dead space inside a catheter body tube compared to multiple fiber optic bundles but may still have residual dead space, which consists of the distal fiber window cladding and the outside wall of the metal tip or catheter tube that holds the window. Using a tapered metal tip, as disclosed for a liquid filled catheter in co-owned patent application number U.S. patent application Ser. No. 13/651,070, Publication No. 2013/0096545, filed by J. Laudenslager et al., on Oct. 12, 2012, titled Small Flexible Liquid Core Catheter for Laser Ablation in Body Lumens and Methods for Use, which is hereby incorporated by reference herein in its entirety, minimizes the initial dead space. For example, a 5 French liquid filled ablation catheter with a tapered metal tip may have a 70 percent active area at the tip that gradually reduces to 42 percent once the catheter tip penetrates the target past the tapered metal sheath. Multiple fiber optic based catheters, ignoring the guide wire lumen, may have about 17 percent to 30 percent active cutting area in some cases depending on the design at the tip. Multiple fiber optic based catheters may need to be operated at higher energy fluences and repetition rates compared to fluences and repetition rates of single fiber optic systems or the like in order to cut as efficiently as a laser ablation catheter having a homogenous laser energy output at the output surface of the distal optical window.
Liquid core laser ablation catheters discussed herein have less dead space and needs less energy density to ablate tissue compared generally to multiple fiber optic laser ablation catheter designs currently in commercial use. The reduced dead space (that distal surface area that is not emitting laser energy) may be an important feature for ablation of blockages in arteries and for the ability of the laser ablation catheter to cross a lesion in a patient's vessel. Some embodiments of liquid core laser ablation catheters may incorporate an optical window having an expanded segment with a stepped configuration which is configured to increase the output surface of the liquid core laser ablation catheter, minimize the dead space of the liquid core laser ablation catheter, and allow for easier passage of the liquid core laser ablation catheter through tight lesions which are disposed within the vasculature of a patient with less pulse energy needed.
Some embodiments of a laser ablation system may include a laser energy source and a liquid core laser ablation catheter. Some embodiments of the system may also include a laser coupler which is disposed at a proximal section of the liquid core laser ablation catheter. The liquid core laser ablation catheter may include a working length section which is disposed between the proximal section and a distal section of the liquid core laser ablation catheter. The working length section of the liquid core laser ablation catheter may include a catheter body tube which may feature an inner lumen which is disposed within the catheter body tube.
In some cases, the inner lumen may be coated with an optical coating, with the optical coating spanning the working length section. An optical fluid may be disposed within a core liquid volume at least partially bounded by the inner lumen of the catheter body tube, with the optical fluid being in optical communication with the laser coupler. The distal section of the liquid core laser ablation catheter may include a window housing having a tubing cavity which may be secured to the catheter body tube. An optical window may be partially disposed within and secured to the window housing, in optical communication with the optical fluid.
Some embodiments of the distal optical window may include an expanded segment which has an outer radial surface that extends radially beyond an outer radial surface of an insert segment of the optical window, with an outer surface of the insert segment being configured to couple to an interior window surface of the window housing. The expanded segment may extend distally beyond a distal portion and/or distal end of the window housing. In some cases, the outer diameter of the expanded segment may be equal to or greater than an outer diameter of the window housing, thereby allowing optical energy which exits the optical window through an output surface of the expanded segment to ablate a surface area of target material which is greater than or equal to the surface area of the distal section of the liquid core laser ablation catheter. In some cases the optical window which includes the insert segment and the expanded segment may be formed from a single length of ultraviolet grade silica over silica core-clad fiber optic.
Some liquid core laser ablation catheter embodiments may be configured such that optical energy may be transmitted from the laser energy source through the laser coupler, through the optical fluid which disposed within the core liquid volume in the inner lumen of the catheter body tube, through the optical window where it exits the output surface of the expanded segment, and into target tissue and/or target material which is to be ablated by the optical energy. In some cases the laser energy source may be configured as an ultraviolet laser and the optical energy may be configured as pulsed ultraviolet energy, with each ultraviolet energy pulse having sufficient pulse energy to ablate blockages in body lumens at the distal tip of the liquid core laser ablation catheter when it is curved around typical bends in a patient's vascular system. Some laser energy sources may be configured as an XeCl excimer laser with a wavelength around 308 nm, with a pulse duration greater than about 10 nanoseconds (nsec), a pulse energy fluence greater than about 6 milli-Joules per millimeter squared (mJ/mm2) delivered to the distal tip of the liquid core laser ablation catheter and a repetition rate range of about 10 Hertz (Hz) to about 100 Hz. In some cases, such laser energy sources may be operated with pulse durations less than about 300 nsec, more specifically, less than about 100 nsec.
Some distal optical window embodiments may be formed monolithically from a single uninterrupted piece of feed fiber optic which is made of ultraviolet grade silica over silica which form a core and cladding of the feed fiber optic. The expanded segment of the optical window may be formed by melting a portion of the core-cladding materials of the feed fiber optic into a melted portion and forming the expanded segment from the melted portion. The portion of the feed fiber optic which has not been melted may include the insert portion of the optical window. In some cases, within the expanded segment of the optical window the cladding material may be mixed with the core material resulting in an expanded segment of the distal optical window that has no cladding or waveguide configuration, nor does it have any dead space. An outer diameter of the expanded segment may be larger than an outer radial diameter of the insert segment, and the diameter of the expanded segment may be greater than or equal to diameters of the tip or distal edge of the window housing and/or the catheter body tube proximally adjacent the distal optical window which may have a stepped configuration in some cases.
For some embodiments of distal optical windows (which may typically serve as output optical windows), the axial length of the expanded segment may be configured to be long enough to allow for an optical beam to expand to an outer diameter of the output surface of the expanded segment. The length of the expanded segment may also be configured to be axially short enough to allow for passage through tortuous pathways within a human patient's anatomical lumen. For some embodiments of such a distal optical window, the overall length of the optical window may be from about 4 millimeters (mm) to about 8 mm. For some embodiments of the optical window, the axial length of the expanded segment may be from about 0.5 mm to about 2 mm, more specifically, about 1 mm to about 2 mm in some cases. For some embodiments, the axial length of the expanded segment 48 may be 0.9 mm to 1.1 mm. The ratio of the diameter of the expanded segment to the diameter of the insert segment may be about from about 1.1:1 to about 1.5:1 in some cases.
Some or all of the edges of any distal optical window embodiments discussed herein may be filleted, rounded or chamfered in order to minimize damage or chipping during assembly, and to prevent trauma to adjacent tissue when disposed within a body lumen. For some optical window embodiments, the expanded segment and the insert segment of the optical window may be monolithically formed from sapphire window material or substrate including a feed fiber optic substrate. Some embodiments of optical windows having an expanded segment and an insert segment may be formed monolithically from a single piece of material, while other embodiments of optical windows having an expanded segment and an insert segment may be formed by welding or fusing different pieces of material together.
A working length 42 of the liquid core laser ablation catheter 24 may include the length inside the patient's body between the access point and the target tissue lesion site and the length outside the patient's body necessary to couple or pass through the Y-adapter. An additional length may be needed to couple the working length 42 of 50 centimeters (cm) to 120 cm to the laser source 12 in some cases. If a laser source 12 is large and located away from the patient, an additional working length 42 may be necessary. Some liquid core laser ablation catheter embodiments 24 may be from about 2 meters to about 3 meters long in some cases.
In some cases, the laser source 12 of the laser system 10 may include a XeCl excimer laser which produces high energy pulses at a wavelength of about 308 nm, for example, 307 nm to 309 nm, however, other high energy pulsed ultraviolet laser sources may be used. Some laser source embodiments 12 may have a pulse duration of less than about 100 nsec and a repetition rate of up to about 100 Hz. Some such laser source embodiments 12 may be capable of producing about 20 milli-Joules per pulse (mJ/pulse) to about 100 mJ/pulse. For some embodiments, the transmission of laser optical energy through the liquid core laser ablation catheter with solid windows may be high enough to enable a relatively small laser source 12 to be used for the laser ablation system 10 in order to save cost and valuable catheter lab space. In contrast some previous embodiments of ablation catheters having multiple fibers may have considerable dead space at the input laser coupler, which requires a certain energy density over a larger area and hence requires higher laser optical energy output and a larger more expensive laser source 12 to achieve ablation of the target atheroma. In addition, the large dead space at the distal end of such ablation catheters having multiple fibers may require a higher energy fluence in order to overcome the dead space for efficient ablation of atheroma.
Some embodiments of the window housing 50 may include a tapered section 51 as shown in
For some embodiments of the liquid core laser ablation catheter 24, an exterior surface 54 of the insert segment 46 of the optical window 44 may be bonded to an interior window surface 56 of the window housing 50 using a suitable adhesive 58 as shown in
The expanded segment 48 of the distal optical window 44 may extend beyond a distal edge 68 of the window housing 50 as shown in
For some embodiments, the insert segment 46 of the distal optical window 44 which includes a waveguide fiber optic structure which may have a numerical aperture (NA) in the waveguide structure greater than or equal to a NA of the optical fluid 55 in combination with the inner surface 76 of the catheter body tube 52 in order to minimize optical losses at the transition between optical fluid 55 and the distal optical window 44. That is, the optical fluid 55 disposed within the interior lumen 53 of the catheter body tube 52 forms a waveguide structure in combination with an inner layer or surface 76 of the catheter body tube 52 based on the respective IRs of the optical fluid 55 and inner layer 67 so as to include a waveguide structure for the catheter body tube 52 having an NA that is dependent upon those respective IRs. Generally speaking, a first IR of the inner layer 67 is less than a second IR of the optical fluid 55 to produce a waveguide configuration. In some cases, the distal optical window 44 may include a high NA optical fiber or a silica rod which is coated with a relatively low numerical index of refraction material such as an amorphous fluoropolymer coating or a dielectric coating that is transparent or reflective of the optical energy laser pulse, which may include an ultraviolet energy pulse.
In use, the liquid core laser ablation catheter 24 may function to ablate target materials or tissue as follows. Referring to
An embodiment of a liquid core laser ablation catheter 92 that does not include an expanded segment on a distal optical window is shown in
Pulsed ultraviolet excimer laser ablation catheter embodiments which have been discussed herein may be configured to remove various types of atheroma by photochemical, photo-thermal and photo-acoustic processes. With this ablative method the irradiated tissue may be removed with little to no thermal damage to the edges of the lumen wall of the patient, because the nanosecond pulse duration of the ultraviolet pulsed excimer laser currently used for this application is at time scales much less than the thermal diffusion time of the absorbed optical energy. The pulsed optical energy from the laser must be delivered inside the body lumen with a flexible fiber optic or waveguide that can pass the tortuosity of the arterial anatomy of a patient's body to get to the site of the blockage. A single fiber optic might present an efficient cutting surface, but because the catheter size is in the range of 1 mm to 2.5 mm diameter for the ablation surface, these single fibers at this diameter are too stiff for percutaneous use in a patient's body lumen.
Some previous embodiments of ablation catheters use many small diameter fiber optics, typically with cores having diameters of about 50 microns in quantities of about 100 fiber optics to about 300 fiber optics, arranged in a bundle to provide a flexible ablation catheter in a 1 mm to 2.5 mm diameter. Unfortunately, this cutting surface configuration may produce a “Swiss cheese” type dead space geometry due to the cladding, packing factor of the multiple fibers, and the outer tube wall thickness. It has been demonstrated that this configuration does not cut as efficiently as a surface with less dead space (such as an ablation catheter which is configured with a single fiber optic) and requires more energy and a higher pulse rate to ablate target tissue.
As has been discussed, an improvement to multiple fiber laser ablation catheters is the liquid core laser ablation catheter 92 with a solid distal optical window 94 which is disposed at a distal section 60 of the liquid core laser ablation catheter 92. However, there may still be some residual dead space due to the cladding material 66 on the distal optical window 94 and the catheter body tube 52 that contains the optical fluid 55 and the distal optical window 94. Although this ablation catheter 92 configuration requires lower pulsed optical energy to ablate through target material, the ablation hole which is created may be slightly smaller than the outside surface of the ablation catheter 92 in some cases. This may result in resistance to passage of the ablation catheter 92 through target material such as a lesion, especially for a non-compliant lesion such as calcified lesions.
Laser ablation catheters which incorporate the window housing 50 which includes the tapered section 51 may have improved maneuvering through tortuous lesion sites when compared to ablation catheters which do not have tapered window housings. This is due to the fact that laser ablation catheters which incorporate the window housing 50 which includes the tapered section 51 have a reduced profile at the catheter distal section 60 which can more easily pass through tortuous lesion sites within the vasculature of a patient.
The addition of the distal optical window 44 which incorporates the expanded segment 48 as has been discussed may further improve the ability of a given laser ablation catheter (such as liquid core laser ablation catheter 24) to ablate through target material 90. Optical energy 89 which enters the distal optical window 44 may be transmitted through the insert segment 46 of the optical window 44 (where it may be optically contained by a cladding material 66) and into the expanded segment 48, that does not include a cladding layer to serve as a waveguide, where it may diverge and exit the expanded segment 48 through the output surface 80 of the distal optical window 44. The surface area of the output surface 80 of the distal optical window 44 may in some cases be greater than or equal to the area of elements which are disposed at the distal section 60 of the respective laser ablation catheter such as the window housing 50 or the catheter body tube 52.
Some ablation catheters which utilize the distal optical window 44 having an insert segment 46 and an expanded segment 48 may have no dead space at the output surface 80 of the distal optical window 44. As an example consider an ablation experiment conducted utilizing two ablation catheters which incorporate the same size 5 French (1.57 mm) catheter body tube 52 and a 1.22 mm tapered tip diameter at the distal end. A first ablation catheter incorporated a 1 mm diameter distal optical window (constant diameter distal optical window similar to embodiment 92 in
The area of the output surface of a given distal optical window is proportional to the diameter of the distal optical window squared. Thus for the given example the distal optical window 44 configured with the expanded segment 48 (1.22 mm diameter) produces a 49 percent larger ablation area (output surface 80) for the same diameter optic window 94 (1 mm diameter core) with a constant diameter on the same size catheter (5 French). In some cases, the pulse energy from the laser may need to be increased in order to achieve the appropriate energy fluence over the larger output surface 80 of the expanded segment 48 of the distal optical window 44.
As has been discussed, the expanded segment 48 of the distal optical window 44 may be configured with an output surface 80 which has a surface area which is equal to or greater than a surface area of a cross section of the ablation catheter 24. For some embodiments for treating peripheral arterial disease where tortuosity is less severe, the distal optical window 44 may incorporate an insert segment 46 (typically 5 to 8 mm length for some embodiments) which may be formed from a single length of feed fiber optic. The insert segment 46 may be disposed within the window housing 50 and/or the catheter body tube 52 of the liquid core laser ablation catheter 52. For some embodiments, a proximal portion 59 of the insert segment 46 may extend proximally from the interior of the window housing 50 and into the inner lumen 53 of the catheter body tube 52 as shown in
In some cases the distal optical window 44 may be formed from a suitably configured feed fiber optic. The expanded segment 48 may be formed by melting the cladding material 66 of the feed fiber optic into the inner core of the feed fiber optic within a distal segment of the feed fiber optic, and then shaping the glass within the distal segment into the expanded segment 48 after shaping the entire distal optical window 44 may be annealed to reduce or remove any stress in the material of the distal optical window 44. After being formed, the distal optical window 44 may be secured (using any suitable adhesive for example) into a suitably configured window housing 50 (as shown in
Some embodiments of the window housing 50 may include at least one crimp ridge 67 which may be disposed circumferentially about and extend into the tube cavity 62 of the window housing 50. Each crimp ridge 67 may assist in securing the window housing 50 to the catheter body tube 52 after the crimping process. Each crimp ridge 67 may be configured as an annular protrusion which extends from an inner surface of the crimped portion of the tube cavity 62 of the window housing 50 (see
For some embodiments, multiple crimp ridges 67 may be disposed such that they are axially spaced along the interior surface of the tube cavity 62 as shown in
Thus, the laser coupler 26 may be optically coupled to the optical fluid 55 which is disposed within the inner lumen 53 of the catheter body tube 52. The optical fluid 55 is in turn optically coupled to the input surface 78 of the distal optical window 44. The input surface may in turn be optically coupled to the output surface 80 of the distal optical window 44 by the insert segment 46 and the expanded segment 48 of the distal optical window 44. As has been discussed, cladding material 66 may be disposed on the outside surface 54 of the insert segment 46 with the cladding material forming a waveguide configuration facilitating the transmission of optical energy 89 through the insert segment 46.
In some cases, the catheter body tube 52 may be a fluoropolymer tube. The distal end 60 of the fluoropolymer tube 52 may be notched to a reduced outer diameter to attach the window housing 50 such that a proximal portion 64 of the window housing 50 matches the outside diameter of the catheter body tube 52 after the window housing 50 has been crimped to the catheter body tube 52. In some cases, the window housing 50 which secures the distal optical window 44 may also act as a radiopaque marker to locate the distal portion 38 of the liquid core laser ablation catheter 24 during a procedure which utilizes x-ray fluoroscopy.
The typical NA of waveguide functioning portions of distal optical window embodiments 44 formed from ultraviolet transmitting silica over silica fiber optics may be about 0.22, thus providing a full cone angle of optical energy 89 of about 25 degrees. The NA of the feed fiber within the insert segment 46 of the distal optical window 44 may transmit through the expanded segment 48 of the distal optical window 44. In some cases, the cladding material 66 may be removed from the expanded segment 48 of the distal optical window 44 during the formation of the distal optical window 44. In some cases the optical energy 89 which is transmitted through the insert segment 46 (which may be configured as an optical feed fiber) of the distal optical window 44 expands in a full cone angle into the expanded segment 48 as determined by the numerical aperture of the feed fiber which for some embodiments may include a full cone angle of optical energy 89 of about 25 degrees as shown in
The distribution 91 of the optical energy 89 at the output surface 80 of the distal optical window 44 may be somewhat Gaussian (again see
For some embodiments the catheter body tube 52 may be attached to the window housing 50 by crimping the proximal portion 64 of the window housing 50 onto a distal portion 60 of the catheter body tube 52 and a respective proximal portion 59 of the distal optical window 44. In this manner the distal portion 60 of the catheter body tube 52 is crimped to the proximal portion 59 of the distal optical window 44 by the proximal portion 64 of the window housing 50 which may produce a liquid tight seal between the catheter body tube 52 and the distal optical window 44 such that the inner lumen 53 is sealed at the distal end of the catheter body tube 52 by the distal optical window 44. A tube outer surface 61 of the catheter body tube 52 may be configured to couple to a housing inner surface 69 of the window housing 50. In some cases, the outer surface 61 at the distal portion 60 may be stepped to a reduced outer diameter such that after crimping the window housing 50 over the distal portion, the transition of the outer surface between the catheter body tube 52 and the window housing 50 is smooth. For some embodiments, the distal portion 60 of the catheter body tube 52 may be bonded into the proximal portion 64 of the window housing 50 with a suitable adhesive 58 such as medical grade class VI epoxy for fiber optics, with the adhesive 58 being disposed between the outer surface 61 of the catheter body tube 52 and housing inner surface 69. In some cases, an inner lumen of the proximal portion 64 of the window housing 50 may be expanded to an inside diameter which is greater than an outside diameter of the distal portion 60 of the catheter body tube 52 in order to facilitate assembly of the device and couple to the distal portion 60 of the catheter body tube 52. In turn, as discussed above, the distal portion 60 of the catheter body tube 52 may optionally be notched or suitably tapered in order to couple to the proximal portion 64 of the window housing 50 thereto.
In some cases, it may be desirable to have the distal optical window 44 configured as a modified fiber optic because a distal optical window which is configured as a bare ultraviolet silica rod would fail optically as a waveguide. This is because either the adhesive 58 or the window housing 50 inner surfaces (56, 69) of the window housing 50 would absorb the optical energy 89 configured as ultraviolet light, or any other suitable wavelength range of optical energy, which is transmitted through the distal optical window 44 for such an embodiment, as it would not be refracted from the interface between the distal optical window 44 and the adhesive 58. This is because such an adhesive 58 is not likely to be configured to transmit or refract the optical energy 89. In order to properly function as a waveguide, such a bare window substrate would need to be coated with a low index of refraction coating, a dielectric, reflective metallic coating or the like. In some cases the axial length 74 of the expanded segment 48 of the distal optical window 44 may be only about 1 mm, and the exit angle of the optical energy 89 emitted from the insert segment 46 may have a full cone angle of about 25 degrees into the expanded segment 48 (as shown in
In some cases it may be desirable to improve the distribution 91 of the optical energy 89 (see
For some liquid core laser ablation catheter embodiments, the process of crimping the window housing 50 onto the catheter body tube 52 and the distal optical window 44 offers improved adhesion strength over some previous embodiments particularly since adhesives do not typically bond well onto fluoropolymers such as Teflon® or FEP. The distal optical window 44 may be bonded to the window housing 50 as has been previously discussed, and the proximal section 64 of the window housing 50 may be configured to couple to a distal section 60 of the catheter body tube 52. The proximal section 64 of the window housing 50 may then be crimped onto the distal section 60 of the catheter body tube 52 and the insertion segment 46 of the distal optical window 44 by any suitable means. For example, the crimping process may be accomplished by a suitably configured crimping machine.
The compression of the window housing 50 onto the catheter body tube 52 and the insert segment 46 of the distal optical window 44 may act to form a hermetic seal between the window housing 50 and the catheter body tube 52 in some cases. The crimped configuration, particularly with the use of internal ridges 67 that penetrate an outer wall of the distal section 60 of the catheter body tube 52, may also improve adhesion strength of the junction between the window housing 50, the distal optical window 44 and the catheter body tube 52. The strength of this junction may in some instances be indicated by destructive pull force testing which may be performed on multiple such assemblies. In some cases the ridges 67 upon being embedded in the wall material of the distal section 60 of the catheter body tube 52 may mechanically capture the distal section 60 to the window housing 50 which may be particularly useful for embodiments using fluoropolymers (such as FEP) for the catheter body tube 52 which may have a very low coefficient of friction and be generally slippery and ill suited for adhesive bonding. Improved adhesion strength may be achieved with the use of a distal optical window embodiment 44 which is formed from a fiber optic. The distal optical window 44 formed from a fiber optic may be configured with a length which is long enough to achieve a good hermetic seal, but with the overall length 74 of the distal optical window 44 being axially short enough to keep the distal section 60 of the ablation catheter 24 flexible so as to maintain the capability of going through curves in a patient's anatomy such as vascular lumens and the like.
The entirety of each patent, patent application, publication and document referenced herein hereby is incorporated by reference. Citation of the above patents, patent applications, publications and documents is not an admission that any of the foregoing is pertinent prior art, nor does it constitute any admission as to the contents or date of these publications or documents.
Modifications may be made to the foregoing without departing from the basic aspects of the embodiments discussed. Although embodiments have been described in substantial detail with reference to one or more specific embodiments, those of ordinary skill in the art will recognize that changes may be made to the embodiments specifically disclosed in this application, yet these modifications and improvements are within the scope and spirit of the disclosure.
Embodiments illustratively described herein suitably may be practiced in the absence of any element(s) not specifically disclosed herein. Thus, for example, in each instance herein any of the terms “comprising,” “consisting essentially of,” and “consisting of” may be replaced with either of the other two terms. The terms and expressions which have been employed are used as terms of description and not of limitation and use of such terms and expressions do not exclude any equivalents of the features shown and described or portions thereof, and various modifications are possible. The term “a” or “an” can refer to one of or a plurality of the elements it modifies (e.g., “a reagent” can mean one or more reagents) unless it is contextually clear either one of the elements or more than one of the elements is described. Thus, it should be understood that although embodiments have been specifically disclosed by representative embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and such modifications and variations are considered within the scope of this disclosure.
Certain embodiments of the technology are set forth in the claim(s) that follow(s).
This application is a continuation of copending U.S. patent application Ser. No. 15/359,412, now U.S. Pat. No. 10,555,772, filed Nov. 22, 2016, entitled LASER ABLATION CATHETERS HAVING EXPANDED DISTAL TIP WINDOWS FOR EFFICIENT TISSUE ABLATION, by J. Laudenslager et al., which claims priority under 35 U.S.C. Section 119(e) from U.S. Provisional Patent Application Ser. No. 62/258,836, filed Nov. 23, 2015, by J. Laudenslager et al., titled ENLARGED SHAPED DISTAL WINDOW TIPS FOR LASER ABLATION CATHETERS, each of which is incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3740113 | Cass | Jun 1973 | A |
3995934 | Nath | Dec 1976 | A |
4009382 | Nath | Feb 1977 | A |
4045119 | Eastgate | Aug 1977 | A |
4380460 | Otstot et al. | Apr 1983 | A |
4516972 | Samson et al. | May 1985 | A |
4530569 | Squire | Jul 1985 | A |
4641912 | Goldenberg | Feb 1987 | A |
4686979 | Gruen et al. | Aug 1987 | A |
4720166 | Ohmori et al. | Jan 1988 | A |
4732448 | Goldenberg | Mar 1988 | A |
4739768 | Engleson | Apr 1988 | A |
4747405 | Leckrone | May 1988 | A |
4747662 | Fitz | May 1988 | A |
4762129 | Bonzel | Aug 1988 | A |
4770653 | Shturman | Sep 1988 | A |
4784132 | Fox et al. | Nov 1988 | A |
4784135 | Blum et al. | Nov 1988 | A |
4793359 | Sharrow | Dec 1988 | A |
4799754 | Goldenberg | Jan 1989 | A |
4800876 | Fox et al. | Jan 1989 | A |
4834093 | Littleford et al. | May 1989 | A |
4844062 | Wells | Jul 1989 | A |
4848336 | Fox et al. | Jul 1989 | A |
4850351 | Herman et al. | Jul 1989 | A |
4862886 | Clarke et al. | Sep 1989 | A |
4907133 | Nath | Mar 1990 | A |
4913142 | Kittrell et al. | Apr 1990 | A |
4919508 | Grace et al. | Apr 1990 | A |
4927231 | Levatter | May 1990 | A |
4930863 | Croitoriu et al. | Jun 1990 | A |
4998794 | Holzman | Mar 1991 | A |
5005944 | Laakmann et al. | Apr 1991 | A |
5037404 | Gold et al. | Aug 1991 | A |
5040548 | Yock | Aug 1991 | A |
5041108 | Fox et al. | Aug 1991 | A |
5061273 | Yock | Oct 1991 | A |
5076659 | Bekiarian et al. | Dec 1991 | A |
5100388 | Behl et al. | Mar 1992 | A |
5157750 | Grace et al. | Oct 1992 | A |
5165773 | Nath | Nov 1992 | A |
5176674 | Hofmann | Jan 1993 | A |
5188632 | Goldenberg | Feb 1993 | A |
5263952 | Grace et al. | Nov 1993 | A |
5267341 | Shearin | Nov 1993 | A |
5267993 | Grace et al. | Dec 1993 | A |
5290277 | Vercimak et al. | Mar 1994 | A |
5304171 | Gregory et al. | Apr 1994 | A |
5321783 | Nielson et al. | Jun 1994 | A |
5350395 | Yock | Sep 1994 | A |
5374266 | Kataoka et al. | Dec 1994 | A |
5395361 | Fox et al. | Mar 1995 | A |
5412750 | Nath | May 1995 | A |
5419760 | Narcisco, Jr. | May 1995 | A |
5429604 | Hammersmark et al. | Jul 1995 | A |
5429617 | Hammersmark et al. | Jul 1995 | A |
5438873 | Wlodarczyk et al. | Aug 1995 | A |
5456680 | Taylor et al. | Oct 1995 | A |
5484433 | Taylor et al. | Jan 1996 | A |
5497441 | Croitoru et al. | Mar 1996 | A |
5514128 | Hillsman et al. | May 1996 | A |
5573531 | Gregory | Nov 1996 | A |
5584558 | Nath | Dec 1996 | A |
5675689 | Nath | Oct 1997 | A |
5722972 | Power | Mar 1998 | A |
5737473 | Nath | Apr 1998 | A |
5836940 | Gregory | Nov 1998 | A |
5857052 | Nath | Jan 1999 | A |
5868665 | Biggs | Feb 1999 | A |
5976093 | Jang | Nov 1999 | A |
5989243 | Goldenberg | Nov 1999 | A |
6022309 | Celliers et al. | Feb 2000 | A |
6106510 | Lunn et al. | Aug 2000 | A |
6117128 | Gregory | Sep 2000 | A |
6143013 | Samson et al. | Nov 2000 | A |
6163641 | Eastgate | Dec 2000 | A |
6165163 | Chien et al. | Dec 2000 | A |
6212422 | Berg et al. | Apr 2001 | B1 |
6263236 | Kasinkas et al. | Jul 2001 | B1 |
6306124 | Jones et al. | Oct 2001 | B1 |
6314226 | Nath | Nov 2001 | B1 |
6314227 | Nath | Nov 2001 | B1 |
6368318 | Visuri et al. | Apr 2002 | B1 |
6418257 | Nath | Jul 2002 | B1 |
6507688 | Nath | Jan 2003 | B1 |
6520934 | Lee et al. | Feb 2003 | B1 |
6571049 | Nath | May 2003 | B1 |
6585760 | Fogarty | Jul 2003 | B1 |
6609014 | Allison et al. | Aug 2003 | B1 |
6824553 | Samson et al. | Nov 2004 | B1 |
6893427 | Jimenez | May 2005 | B1 |
6963688 | Nath | Nov 2005 | B2 |
6974473 | Barclay et al. | Dec 2005 | B2 |
7050692 | Harlen et al. | May 2006 | B2 |
7144248 | Irwin | Dec 2006 | B2 |
7144381 | Gertner | Dec 2006 | B2 |
7167622 | Temelkuran et al. | Jan 2007 | B2 |
7402151 | Rosenman et al. | Jul 2008 | B2 |
7572254 | Herbert et al. | Aug 2009 | B2 |
7762980 | Gertner | Jul 2010 | B2 |
8152795 | Farr et al. | Apr 2012 | B2 |
8231551 | Griffin et al. | Jul 2012 | B2 |
8652084 | Akingba | Feb 2014 | B2 |
9339628 | Adams et al. | May 2016 | B2 |
9700655 | Laudenslager | Jul 2017 | B2 |
9962527 | Laudenslager et al. | May 2018 | B2 |
10384038 | Laudensalger et al. | Aug 2019 | B2 |
10478251 | Shuffler et al. | Nov 2019 | B2 |
10485613 | Hendrick et al. | Nov 2019 | B2 |
10492876 | Anastassiou et al. | Dec 2019 | B2 |
10555772 | Laudenslager | Feb 2020 | B2 |
10799671 | Shimada et al. | Oct 2020 | B2 |
20030023236 | Ashok et al. | Jan 2003 | A1 |
20030078569 | Caldera et al. | Apr 2003 | A1 |
20030158561 | Kanesaka | Aug 2003 | A1 |
20040220473 | Lauldi | Oct 2004 | A1 |
20050031281 | Nath | Feb 2005 | A1 |
20050254237 | Nath et al. | Nov 2005 | A1 |
20060253048 | Jones et al. | Nov 2006 | A1 |
20060271090 | Shaked et al. | Nov 2006 | A1 |
20070244495 | Kwon | Oct 2007 | A1 |
20080188793 | Kozak et al. | Aug 2008 | A1 |
20080249515 | Taylor | Oct 2008 | A1 |
20090112198 | Khanna et al. | Apr 2009 | A1 |
20090163899 | Burton et al. | Jun 2009 | A1 |
20090227997 | Wang et al. | Sep 2009 | A1 |
20090254074 | Splinter et al. | Oct 2009 | A1 |
20090264898 | Miller et al. | Oct 2009 | A1 |
20100004607 | Wilson et al. | Jan 2010 | A1 |
20100016842 | Fix | Jan 2010 | A1 |
20100087783 | Weber et al. | Apr 2010 | A1 |
20100114081 | Keeler et al. | May 2010 | A1 |
20100152720 | Sauro et al. | Jun 2010 | A1 |
20100198193 | Trapp | Aug 2010 | A1 |
20110238041 | Lim et al. | Sep 2011 | A1 |
20120277671 | Fuentes | Nov 2012 | A1 |
20130096545 | Laudenslager | Apr 2013 | A1 |
20150057639 | Storbeck et al. | Feb 2015 | A1 |
20150105714 | Laudenslager et al. | Apr 2015 | A1 |
20170143424 | Laudenslager et al. | May 2017 | A1 |
20170266351 | Laudenslager et al. | Sep 2017 | A1 |
20180008348 | Grace et al. | Jan 2018 | A1 |
20180021550 | Laudenslager et al. | Jan 2018 | A1 |
20180021551 | Laudenslager et al. | Jan 2018 | A1 |
20180021552 | Laudenslager et al. | Jan 2018 | A1 |
20180250498 | Stern et al. | Sep 2018 | A1 |
20190142517 | Chia et al. | May 2019 | A1 |
20190160259 | Cottone et al. | May 2019 | A1 |
20190290356 | Wood et al. | Sep 2019 | A1 |
20190366036 | Jalgaonkar et al. | Dec 2019 | A1 |
20200046429 | Tschida et al. | Feb 2020 | A1 |
20200230294 | Laudenslager et al. | Jul 2020 | A1 |
20200261154 | Ogata et al. | Aug 2020 | A1 |
Number | Date | Country |
---|---|---|
1652722 | Aug 2005 | CN |
1832708 | Sep 2006 | CN |
0247746 | Dec 1987 | EP |
0368512 | May 1990 | EP |
0590268 | Apr 1994 | EP |
0727054 | Aug 1996 | EP |
1757428 | Feb 2007 | EP |
2301617 | Mar 2011 | EP |
WO 95012138 | May 1995 | WO |
WO 97039691 | Oct 1997 | WO |
WO 98038538 | Sep 1998 | WO |
WO 00030696 | Jun 2000 | WO |
WO 09120871 | Oct 2009 | WO |
Entry |
---|
Invitation to Pay Additional Fees, dated Apr. 29, 2021 in International Patent Application No. PCT/US2021/019199 filed: Feb. 23, 2021. |
Notice of Allowance dated Jun. 17, 2021 in U.S. Appl. No. 16/359,889, filed Mar. 20, 2019. |
“Prevalence and Cost of ESRD Therapy,” USRDS Annual Data Report 1991, American Journal of Kidney Diseases, vol. 18, No. 3, Suppl 2, Nov. 1991; pp. 21-29. |
Bittl; Catheter Interventions for Hemodiaylysis Fistula and Grafts: J Am Coll Cardiol Intv vol. 3 pp. 1-11 (2010). |
Das, “Excimer Laser-Assisted Angioplasty for Infrainguinal Artery Disease” J of Endovasc Therapy vol. 16 pp. 1198-11104(2009). |
Drooz, “Ultrahigh-pressure angioplasty of a transposed brachiocephalic fistula with recurrent stenosis,” ConQuest PTA Dilation Catheter, Bard Peripheral Vascular, Innova Fairfax Hospital; Fairfax Hospital, Aug. 2005. |
Forauer, Hoffer, et al.; “Dialysis Access Venous Stenoses: Treatment with Balloon Angioplasty-1- versus 3-minute Inflation Times” Radiology vol. 249, pp. 375-381 (2008). |
Gandini and Del Giudice; “Use of laser Atherectomy with drug-eluting balloon angioplasty shows benefit in treatment of in-stent restenosis” presented at EuroPCR 2014 Congress (May 20-23, 2014). |
Haage, Verwerk et al.:“ Percutaneous treatment of thrombosed primary arteriovenus hemodialysis access fistulae” Kidney International, vol. 57, pp. 1169-1175(2000). |
Hamburger et al., New Aspects of Excimer Laser Coronary Angioplasty Physical Aspects and Clinical Results, printed by Optima Grafische Communicatie ISBN 90-73235-27-8, Rotterdam, Jaap N. Hamburger, Dec. 1998. |
Hofstra et al., “Enhanced Cellular Proliferation in Intact Stenotic Lesions Derived From Human Arteriovenous Fistulas and peripheral Bypass Grafts. Does it correlate with Flow Parameters?” Circulation, 1996;94:1283-1290. |
Janis et al. “Laser Thrombolysis in an in vitro Model” Lasers in Surg.: Advanced Characterization, Therapeutics and Systems, Pro. of SPIE vol. 3907 pp. 582-585 (2000). |
Ma et al., “Interaction of excimer laser with blood components and thrombosis” Life Science J. vol. 5 pp. 19-26 (2008). |
Mickley; “Stenosis and thrombus in hemodialysis fistula and grafts: the surgeon's point of view” Nephrol Dial Transplant vol. 19 pp. 309-311 (2001). |
Miller and Friedman, “Balloon-Assisted Maturation of Arteriovenous Fistulas” Endovascular Today Endovascular Today, pp. 46-54 (2010). |
Morph ® “Universal Deflectable Guide Catheder,” BioCardia® Cat # 01037-5. |
Mysliwiec, “Vascular access thrombosis-what are the possibilities of intervention?” Nephrol Dial Transplant (1997) 12: Editorial Comments. |
Ozkan, Gungor et al. “Endovascular Stent Placement of Juxtaanastomotic Stenosis in Native Arteriovenus Fistula After Unsuccessful Balloon Angioplasty” Iranian J of Radiology, vol. 10 pp. 133-139 (2013). |
Papaioannou et al. “Excimer Laser Assisted Thrombolysis: The Effect of Fluence, Repetition Rate and Catheter Size” Proc. SPIE 4609, Lasers in Surgery; Advanced Characterization, Therapeutics and Systems XII 413 (2002). |
Papaioannou et al. “Particulate debris analysis during excimer laser thrombolysis: An in-vitro study” Proc. SPIE 4609, Lasers in Surgery; Advanced Characterization, Therapeutics and Systems XII 404 (2002). |
Shenoy, “Surgical anatomy of upper arm: what is needed for AVF planning” J of Vascul Access vol. 10 pp. 223-232(2009). |
Sofocleous et al.;“Dialysis Fistulas” In Medscape (2013). |
Staniloae et al. “Obrital Atherectomy: Device Evolution and Clinical Data” Periperal Vase. Disease, vol. 26,pp. 215-219 (2014). |
Van den Berg, Pedrotti et al.; “In-Stent Restenosis: Mid-Term Results of Debulking Using Excimer Laser and Drug-Eluting Balloons: Sustained Benefit?” J Invasive Cardiol vol. 26 pp. 333-337(2014). |
Van den Berg; “ Atherectomy and DCB in the SFA: A Summary of the Data” Endovascular Today pp. 28-32(2014). |
Walker et al., “Excimer Laser-Assisted Angioplasty” Endovasc. Today,pp. 75-76 (2007). |
Zaleski; “Declotting, Maintenance, and Avoiding Procedural Complications of Native Arteriovenus Fistulae” Semin Intervent Radiol. vol. 21, pp. 83-93 (2004). |
Zwaan et al., “Initial clinical experience with a new pulsed dye laser device in angioplasty of limb ischemia and shunt fistula obstructions,” European Journal of Radiology, 14 (1992) pp. 72-76. |
Extended European Search Report dated May 29, 2015 in European Patent Application No. EP 12840010.8, filed: Oct. 12, 2012. |
International Preliminary Report on Patentability dated Apr. 24, 2014 in International Application No. PCT/US2012/060065 filed Oct. 12, 2012. |
International Search Report and Written Opinion dated Mar. 29, 2013 in International Application No. PCT/US2012/060065 filed Oct. 12, 2012. |
Notice of Allowance dated Apr. 20, 2017 in U.S. Appl. No. 13/651,070, filed Oct. 12, 2012 and published as: US-2013/0096545 on: Apr. 18, 2013 and issued as: 9,700,655 on Jul. 11, 2017. |
Final Office Action dated Sep. 15, 2016 in U.S. Appl. No. 13/651,070, filed Oct. 12, 2012 and published as: US-2013/0096545 on: Apr. 18, 2013 and issued as: 9,700,655 on Jul. 11, 2017. |
Non-Final Office Action dated Feb. 12, 2016 in U.S. Appl. No. 13/651,070, filed Oct. 12, 2012 and published as: US-2013/0096545 on: Apr. 18, 2013 and issued as: U.S. Pat. No. 9,700,655 on Jul. 11, 2017. |
Notice of Allowance dated Jan. 30, 2018 in U.S. Appl. No. 14/515,435, filed Oct. 15, 2014, published as: 2015/0105714 on Apr. 16, 2015 and issued as: U.S. Pat. No. 9,962,527 on May 8, 2018. |
ExParte Quayle Action dated Dec. 12, 2017 in U.S. Appl. No. 14/515,435, filed Oct. 15, 2014, published as: 2015/0105714 on Apr. 16, 2015 and issued as: U.S. Pat. No. 9,962,527 on May 8, 2018. |
Notice of Allowance dated Apr. 19, 2019 in U.S. Appl. No. 15/723,062, filed Oct. 2, 2017, published as: 2018/0021551 on Jan. 25, 2018. |
Non Final Office Action dated Dec. 31, 2018 in U.S. Appl. No. 15/723,062, filed Oct. 2, 2017, published as: 2018/0021551 on Jan. 25, 2018. |
Non Final Office Action dated Nov. 30, 2018 in U.S. Appl. No. 15/723,057, filed Oct. 2, 2017, published as: 2018/0021550 on Jan. 25, 2018 and issued as: U.S. Pat. No. 10,245,417 on Apr. 2, 2019. |
Notice of Allowance dated Dec. 31, 2018 in U.S. Appl. No. 15/723,057, filed Oct. 2, 2017, published as: 2018/0021550 on Jan. 25, 2018 and issued as: U.S. Pat. No. 10,245,417 on Apr. 2, 2019. |
Notice of Allowance dated Feb. 26, 2019 in U.S. Appl. No. 15/723,057, filed Oct. 2, 2017, published as: 2018/0021550 on Jan. 25, 2018 and issued as: U.S. Pat. No. 10,245,417 on Apr. 2, 2019. |
Notice of Allowance dated Apr. 17, 2019 in U.S. Appl. No. 15/723,067, filed Oct. 2, 2017, published as: 2018/0021552 on Jan. 25, 2018. |
Notice of Allowance dated Feb. 27, 2019 in U.S. Appl. No. 15/723,067, filed Oct. 2, 2017, published as: 2018/0021552 on Jan. 25, 2018. |
ExParte Quayle Action dated Nov. 29, 2018 in U.S. Appl. No. 15/723,067, filed Oct. 2, 2017, published as: 2018/0021552 on Jan. 25, 2018. |
Extended European Search Report dated Aug. 13, 2019 in European Patent Application No. EP 19163464.1, filed: Mar. 18, 2019. |
Notice of Allowance dated Oct. 17, 2019 in U.S. Appl. No. 15/359,412, filed Nov. 22, 2016, published as: 2017/0143424 on May 25, 2017. |
Non-Final Office Action dated Aug. 5, 2019 in U.S. Appl. No. 15/359,412, filed Nov. 22, 2016, published as: 2017/0143424 on May 25, 2017. |
Non-Final Office Action dated Jan. 9, 2020 in U.S. Appl. No. 15/987,838, filed May 23, 2018, published as: 2018/0339136 on Nov. 29, 2018. |
Non-Final Office Action dated Jan. 12, 2021 in U.S. Appl. No. 16/359,889, filed Mar. 20, 2019 and published as: US-2019/0290356 on: Sep. 26, 2019. |
Non-Final Office Action dated Apr. 1, 2021 U.S. Appl. No. 16/549,516, filed Aug. 23, 2019 and published as: US-2019/0374684 on: Dec. 12, 2019. |
Non-Final Office Action dated Sep. 9, 2020 in U.S. Appl. No. 15/615,734, filed Jun. 6, 2017 and published as: US-2017/0266351 on: Sep. 21, 2017. |
Non-Final Office Action dated Sep. 30, 2020 in U.S. Appl. No. 16/502,766, filed Jul. 3, 2019 and published as: US-2019/0336732 on: Nov. 7, 2019. |
International Search Report and Written Opinion dated Jul. 12, 2021 in International Patent Application: PCT/US21/19199 filed Feb. 23, 2021. |
Non-Final Office Action dated Oct. 13, 2021 in U.S. Appl. No. 16/843,736, filed Apr. 8, 2020 and published as: 2020/0230294 on Jul. 23, 2020. |
Number | Date | Country | |
---|---|---|---|
20200138517 A1 | May 2020 | US |
Number | Date | Country | |
---|---|---|---|
62258836 | Nov 2015 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15359412 | Nov 2016 | US |
Child | 16734202 | US |